Seguimiento citogenético y molecular en pacientes con leucemia mieloide crónica y trasplante alogénico de médula ósea

Content Provider	Semantic Scholar
Author	Sánchez, Elizabeth Ruiz Ramírez, Edith Falcón Morales, Enrique Gómez Ibarra, Gregorio Ignacio Valle, Elizabeth Sánchez Anaya, Luis Kofman, Susana Trejo, Rosa María Arana
Copyright Year	2003
Abstract	The genetic hallmark of chronic myelogenous leukemia (CML) is the t(9;22)(q34;q11), this gene fusion leads to the expression of chimeric BCR/ABL messenger RNA (mRNA), this marker is an attractive target for monitoring minimal residual disease (MDR) after bone marrow transplantation (BMT). The RT-PCR assays has become widely used for monitoring MDR after BMT for CML. We reported the cytogenetic and molecular findings in follow-up samples from 15 CML patients undergoing BMT. All 15 patients investigated before BMT by cytogenetic and RT-PCR were positive for Ph1 chromosome and BCR/ABL transcripts. Ten patients in complete remission presented for >12 month BCR/ABL transcript negative and karyotype normal. In five patients the RT-PCR nested for BCR/ABL were positive, three developed disease recurrence, one died by relapse, the other case with BCR/ABL+ for >12 months received donor lymphocyte infusion (DLI), then he has complete remission. We concluded that cytogenetic analysis is limited and insufficient in the monitoring of BMT and the RT-PCR provide reliable information on residual tumor burden in CML patients with BMT. The prognostic significance of a qualitative BCR/ABL can be refined by quantitative assays and this may target patients who would benefit from early intervention therapeutic.
Starting Page	198
Ending Page	202
Page Count	5
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://www.medigraphic.com/pdfs/h-gral/hg-2003/hg034d.pdf
Volume Number	66
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article